🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨 Breaking News U.S. FDA approves #Larotrectinib, 1st targeted cancer drug approved based on mutation rather than tumor type & approved simultaneously for adults and children. Hear more from MSK experts who led the research on this newly approved treatment bit.ly/2DYZteg

Initial results from a first-in-human study show that PET imaging with PD-L1 antibodies outperforms immunohistochemistry- or RNA-sequencing-based biomarkers for prediction of clinical response to #immunotherapy: go.nature.com/2DNW412

Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers academic.oup.com/jnci/advance-a…

FDA approved atezolizumab with chemotherapy and bevacizumab for first-line treatment of metastatic non-squamous #NSCLC with no EGFR or ALK genomic tumor aberrations #lcsm go.usa.gov/xPuzh

An oncologist without a great pathologist is like a hiker in the forest at night without a flashlight #capchat

Retrospective series (with inherent biases that likely inflate efficacy) shows just 13% response rate for afatinib in patients with HER2 mutant lung cancers. Led by my colleague Vicky Lai along with international collaborators #lcsm sciencedirect.com/science/articl…

The neoantigens in #cancer are like Harry Houdini, known for sensational escape acts. In this report, establishing their link to poor outcomes in tumor evolution nature.com/articles/s4158… nature by Charles Swanton Nicholas McGranahan #TRACERx UCL Cancer Institute The Francis Crick Institute and collaborators

Great work led by Alison Schram mentored by Barry S. Taylor on novel use of routine NGS #MSKIMPACT to differentiate between independent primary cancers vs recurrent/metastatic disease where path alone cannot - alters treatment decisions. @sloan_kettering #AACR19

Punchline. TRK inhibitors are highly active in TRK fusion-positive NCLCs. Responses are durable. CNS activity is observed. It is important to include TRK fusion screening as part of comprehensive profiling of NSCLCs. @annaffarago @rdoebele Maurizio Scaltriti Jackie Hechtman David Hyman

Eventos imunomediados e re-exposição a inibidores de checkpoint Fernando Santini Sírio-Libanês #ONCONEWS onconews.com.br/site/noticias/…

How do patients with NSCLC & very high PD-L1 levels ≥90% do with 1st-line pembrolizumab? Multi-institutional collaboration led by outstanding Elizabeth Jimenez Aguilar & Biagio Ricciuti now online Annals of Oncology @BiagioMD Elizabeth Jiménez Dana-Farber academic.oup.com/annonc/advance…

Great day at our Intersections meeting #PrecisionOncology. We are very honored to have two Thoracic Oncology Giants visiting us. Dr Adusumilli and Gʀᴇɢᴏʀʏ Rɪᴇʟʏ, thanks for coming! #hospitalsiriolibanes #mskcc

⁦⁦Fernando Santini⁩ TMB harmonization much needed! Promising results across platforms. tTMB maybe predictive for pembro alone in first line NSCLC. #ESMO2019

Fernando Santini NRG1 fusion+ tumors, Novel Targets for tumor agnostic cancer therapy! #ESMO2019 Alison Schram

Today at our #MolecularTumorBoard session MedOnc fellow Aline Vieira and Sírio-Libanês multidisciplinary team discussed whether germline testing should be guided from somatic findings. Understanding which role each gene plays in tumorigenesis is cornerstone for better decisions!

Be aware of but not worry about TRK inhibitors on-target adverse events! It is the first time to describe the withdrawal pain syndrome and its management. Congratulations Dazhi Liu, Pharm.D, BCOP who always wanted to gather this data! sciencedirect.com/science/articl…

Thanks for the opportunity to present #TiP, on behalf of my co-investigators of #LIBRETTO-431 at #ESMO20; Randomized phase III #Selpercatinib #LOXO292 in treatment-naive #RET +ve #NSCLC. ESMO - Eur. Oncology #LCSM #precisionmedicine CUHK Medicine #AudioLink available: lillyscience.lilly.com/download/3xAUM…

@DrSteveMartin Jarushka Naidoo Patrick Forde The way I balance risks/benefits, at first progression, would try chemo first and then, at progression on chemo, would try re-treatment with pembro. Here are some data to help from once and future colleague Fernando Santini : pubmed.ncbi.nlm.nih.gov/29991499/,

Check out latest Video from Fernando Santini for an update on latest #NTRK fusion data from #ESMO22 & #WCLC22, including long-term efficacy & safety data in #lungcancer with analysis of 17 tumours also highlighting ultra-fast gene fusion assessment approach ow.ly/Fht550L20Ao

I did not expect this piece to resonate with so many people. This is dedicated to all the clinicians in the trenches. thelancet.com/journals/lanha…